From CAF heterogeneity to immune modulation and therapeutic targeting: a subtype-based framework
- 1University of Oxford
Abstract
Cancer-associated fibroblasts (CAFs) are the predominant stromal component in solid tumors, contributing to extracellular matrix (ECM) remodeling, immune regulation, and therapy responses. Once considered homogeneous, CAFs are now recognized as a heterogeneous population comprising subtypes with distinct phenotypes and functions. Their plasticity is shaped dynamically by tumor type, context, and stage. Rather than exhaustively cataloguing the expanding number of CAF subpopulations, this review adopts a function-oriented framework centered on three major CAF subtypes: myofibroblastic CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs), highlighting subtype-specific markers, spatial organization, differentiation trajectory, and immune functions. This review explores the clinical implications of CAF profiling for prognosis and therapy response and discusses emerging strategies that aim to reprogram CAF subtypes or harness their immune-modulatory potential. It also evaluates current CAF-targeting therapies to identify factors contributing to their therapeutic successes and limitations. By integrating subtype-specific immune functions with clinical evidence, this review aims to inform clinicians considering immunotherapy for patients with solid tumors and provide immunologists with a systematic understanding of CAF heterogeneity and directions for future research. These insights position CAFs not only as barriers to treatment but also as potentially programmable components that offer novel therapeutic opportunities.
Related
- Cellular Metabolic Heterogeneity and Therapeutic Targeting in Rheumatoid Arthritis
- Neutrophil dysregulation in sepsis-induced acute lung injury: mechanistic framework and therapeutic targeting by natural products
- Keloid transcriptomics reveal heterogeneity in fibroblast subtype enrichment, gene expression, and immune cell responses
- Multi-dimensional structure and subtype-specific heterogeneity of angiogenesis in breast cancer
- Weekly dynamics, subtype replacement and regional heterogeneity of influenza activity in China, 2024–2026: A national sentinel surveillance analysis
BibTeX
@article{zhang2026from,
title = {{From CAF heterogeneity to immune modulation and therapeutic targeting: a subtype-based framework}},
author = {Tianen Zhang and Shisong Jiang},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1975447},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975447/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From CAF heterogeneity to immune modulation and therapeutic targeting: a subtype-based framework
AU - Tianen Zhang
AU - Shisong Jiang
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1975447
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975447/full
AB - Cancer-associated fibroblasts (CAFs) are the predominant stromal component in solid tumors, contributing to extracellular matrix (ECM) remodeling, immune regulation, and therapy responses. Once considered homogeneous, CAFs are now recognized as a heterogeneous population comprising subtypes with distinct phenotypes and functions. Their plasticity is shaped dynamically by tumor type, context, and stage. Rather than exhaustively cataloguing the expanding number of CAF subpopulations, this review adopts a function-oriented framework centered on three major CAF subtypes: myofibroblastic CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs), highlighting subtype-specific markers, spatial organization, differentiation trajectory, and immune functions. This review explores the clinical implications of CAF profiling for prognosis and therapy response and discusses emerging strategies that aim to reprogram CAF subtypes or harness their immune-modulatory potential. It also evaluates current CAF-targeting therapies to identify factors contributing to their therapeutic successes and limitations. By integrating subtype-specific immune functions with clinical evidence, this review aims to inform clinicians considering immunotherapy for patients with solid tumors and provide immunologists with a systematic understanding of CAF heterogeneity and directions for future research. These insights position CAFs not only as barriers to treatment but also as potentially programmable components that offer novel therapeutic opportunities.
SN - 1664-3224
ER -